Co-Diagnostics Hits a Regulatory Milestone but Faces a One-Quarter Cash Runway

FDA 510(k) submission for Flu/RSV marks a turning point, yet the company's cash position demands urgent action.

CODX · Earnings Call · 2026-08-13

A Regulatory Turning Point

In its second-quarter 2026 report, Co-Diagnostics moved from development toward commercialization in a meaningful way. The company submitted its dual 510(k) and CLIA-waived application to the FDA for the Flu A/B and RSV assay on its PCR platform, a milestone Dwight Egan called "one of the most significant milestones in the company's history." The submission is backed by 27 analytical studies and a clinical study of more than 1,400 symptomatic patients at nine U.S. sites. The company also brought in a new chief scientific officer, Wesley Lindsey, to shepherd the platform through multiple regulatory pathways. “We are pleased to have reached this important stage in the regulatory process.” — Dwight H. Egan, Chief Executive Officer · 2026-08-13

The Cash Clock Is Ticking

But the milestone comes with a stark financial backdrop. CFO Brian Brown reported total revenue of just $166,000 and a net loss of $6.3 million for the quarter. More concerning, the company ended the quarter with only $3.6 million in cash, and cash runway has fallen to approximately one quarter. Brown said the company expects to "continue to evaluate available sources of capital," including equity or debt financings and partnerships, while pursuing nondilutive grants. “We anticipate continued operating losses in the near term.” — Brian L. Brown, Chief Financial Officer · 2026-08-13

Ebola and Tuberculosis: Platform Flexibility in Action

The quarter also demonstrated the platform's versatility beyond respiratory testing. Following the WHO's declaration of a public health emergency for Ebola, CoSara quickly developed a Bundibugyo virus test and completed a proof-of-concept study for an Ebola assay using plasma samples. This is the company's first blood-based assay for the PCR Pro, opening a new application area.

Our strategy with Ebola is a strategy that is designed to be ready when it is needed.
Dwight H. Egan, Chief Executive Officer · 2026-08-13

Separately, the tuberculosis program in India continues to advance, with plans to submit to India's CDSCO and, subject to eligibility, to the WHO's ERPD mechanism this year. The company's NGO partners are largely supporting the validation costs, underscoring the public-health urgency. As Egan noted in the prior quarter, "we've already been through this process a lot in India" “(from the May 2026 call)” — Dwight Egan, Chief Executive Officer · 2026-05-14, referencing 15 existing CDSCO clearances. The company is now poised to localize manufacturing and leverage its established commercial infrastructure.

International Strategy: Long-Brewing, Now Nearing Critical Mass

The India and Saudi Arabia joint ventures (CoSara and CoMira) have been central to the strategy for years. The company's ability to add new applications—like the Ebola test—while advancing TB shows the platform's flexibility, but the near-term solvency is the real question. The stock has been extremely volatile: the recent 90-day tape shows a gain of 19% in four weeks, a spike of 381% in nine days, then a decline of 81% over ten weeks, leaving the stock near its lows. As Egan commented on the COVID test earlier this year, "We don't view it as being a very difficult thing to do" “(from the April 2026 call)” — Dwight Egan, Chief Executive Officer · 2026-04-01, suggesting the team remains confident in its ability to adapt. With a one-quarter cash runway, every regulatory update carries outsized weight. Prior-quarter quotes: (2026-05-14) "we've already been through this process a lot in India" – Egan; (2026-04-01) "We don't view it as being a very difficult thing to do" – Egan.